University of Kansas Alzheimers Disease

堪萨斯大学阿尔茨海默病

• 批准号: 10655210
• 负责人: RUSSELL H. SWERDLOW
• 金额: $ 76.4万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10655210
• 关键词: Accelerometer; Administrative Supplement; Adult; Aerobic Exercise; Age; Aging; Alzheimer disease prevention; Alzheimer' s Disease; Alzheimer’s disease biomarker; Amyloid; Awareness; Biological; Biological Markers; Blood specimen; Body Composition; Cause of Death; Cities; Clinical; Clinical Research; Clinical Services; Clinical Trials; Clinical assessments; Cognitive; Collaborations; Communities; DNA; Data Collection; Data Coordinating Center; Dementia; Development; Diet; Dietary Assessment; Dietary intake; Down Syndrome; Dual-Energy X-Ray Absorptiometry; Energy Metabolism; Enrollment; Food; Funding; Future; Goals; Image; Incidence; Individual; Infrastructure; Intellectual functioning disability; Interdisciplinary Study; Kansas; Left; Life Style; Magnetic Resonance Imaging; Measures; Medical center; Metabolic; Metabolism; Methods; Outcome; Participant; Pathology; Patient Recruitments; Patients; Peripheral Blood Mononuclear Cell; Persons; Pharmaceutical Preparations; Physical activity; Plasma; Positron-Emission Tomography; Program Sustainability; Registries; Research; Resources; Role; Rural Community; Sampling; Secondary to; Site; Standardization; Training; Treadmill Tests; Universities; Urban Community; Weight maintenance regimen; Wichita; aging brain; clinical center; cohort; data repository; distributed data; fitness; investigator-initiated trial; neuroimaging; outreach; prevent; ranpirnase; recruit; research clinical testing; tau Proteins; therapeutic evaluation; trial readiness

ABSTRACT Most adults with Down syndrome (DS) will develop pathology associated with Alzheimer's disease (AD) beginning at ~ age 40. By age 65 the cumulative incidence of dementia exceeds 90% and is the leading cause of death in people with DS. However, individuals with DS have traditionally been left out of many of the national ADRCs clinical cohorts and are not included in state-of-the-art trials developed to prevent, delay, or treat AD. This administrative supplement will support the University of Kansas Alzheimer’s Disease Research Center’s (KU ADRC) clinical core to develop a Down Syndrome (DS) Cohort, which will increase opportunities for the study of DS and AD at KU and beyond. Additionally, to advance the KU ADRCs scientific theme of the role of altered energy metabolism in brain aging and AD, the development of this cohort will allow us to measure metabolic outcomes (e.g. physical activity, aerobic fitness, body composition, and dietary assessment) in individuals with DS and support clinical trials testing the therapeutic potential of manipulating energy metabolism to enable new avenues of research in AD prevention and treatment in individuals with DS. Specifically, we will recruit a well characterized sample of 40 adults with DS for enrollment into collaborating studies. All participants will undergo clinical testing by our clinical core using the NACC DS module which will allow them to be enrolled in a DS registry and available for enrollment in both national cohorts and investigator-initiated trials. Secondarily, to prepare for collaboration with national cohorts and future investigator-initiated trials we will recruit 20 participants from our DS cohort to participate in a trial readiness cohort where we will collect an expanded cognitive battery, blood sample, and neuroimaging assessments (MRI, amyloid PET, and tau PET) harmonized to the methods employed in the Alzheimer’s Biomarker Consortium- Down Syndrome (ABC-DS). Additionally, we will collect metabolic factors such as physical activity, aerobic fitness, body composition, and dietary intake. Creating a dedicated infrastructure and refining our data collection capabilities will enable the KU ADRC to advance local and national studies in DS and dementia and accelerate new avenues of research into the role of metabolism in brain aging and AD in the DS patient.

抽象的 大多数患有唐氏综合症（DS）的成年人都会发展与阿尔茨海默氏病（AD）相关的病理学 从40岁开始。到65岁，痴呆症的累积事件超过90％，是主要原因 DS患者的死亡。但是，传统上，患有DS的人被许多民族遗漏了 ADRCS临床队列，不包括用于预防，延迟或治疗AD的最新试验中。 这种行政补充剂将支持堪萨斯大学阿尔茨海默氏病研究 中心（KU ADRC）临床核心发展唐氏综合症（DS）队列，这将增加机会 用于研究KU及其他地区的DS和AD。此外，要推进Ku Adrcs的科学主题 能量代谢改变在大脑衰老和AD中的作用，该队列的发展将使我们能够 测量代谢结果（例如体育活动，有氧运动，身体成分和饮食 评估）在患有DS和支持临床试验的人中测试操纵治疗潜力的人 能源代谢能够在DS患者的AD预防和治疗方面进行新的研究途径。 具体而言，我们将招募40名成人的良好表征的DS，以注册 协作研究。所有参与者将使用NACC DS进行我们的临床核心进行临床测试 该模块将允许他们入学DS注册表，并可以在两个国家 队列和研究人员发起的试验。其次，为与国家同伙合作做准备 未来研究者发动的试验我们将招募来自DS队列的20名参与者参加试验 准备队列我们将收集扩展的认知电池，血液样本和神经影像学 评估（MRI，淀粉样蛋白宠物和Tau PET）与阿尔茨海默氏症中使用的方法统一 生物标志物联盟 - 唐氏综合症（ABC-DS）。此外，我们将收集代谢因素，例如 体育锻炼，有氧健身，身体成分和饮食摄入量。 创建专门的基础架构并完善我们的数据收集功能将使KU能够 ADRC推进DS和痴呆症的本地和国家研究，并加速研究的新途径 代谢在大脑衰老和AD中的作用在DS患者中。